Detalle Publicación

Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy

Autores: Terpos, E. (Autor de correspondencia); Kostopoulos, I. V.; Kastritis, E.; Ntanasis-Stathopoulos, I. ; Migkou, M. ; Rousakis, P. ; Argyriou, A. T.; Kanellias, N.; Fotiou, D.; Eleutherakis-Papaiakovou, E. ; Gavriatopoulou, M.; Ziogas, D. C.; Papanota, A. M.; Spyropoulou-Vlachou, M.; Trougakos, I. P.; Tsitsilonis, O. E.; Paiva, Bruno; Dimopoulos, M. A.
Título de la revista: HEMASPHERE
ISSN: 2572-9241
Volumen: 3
Número: 6
Páginas: e300
Fecha de publicación: 2019
Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (>= 2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10(-5); 17% at 10(-6). All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts' and tumor-associated monocytes/macrophages' predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10(-6).